

Boehringer Ingelheim Ltda. · Santiago · Chile

Boehringer Ingelheim Ltda.  
Dirección Técnica

6 de octubre de 2016

**REF: Certificación FDA**

**Producto: Pradaxa Cápsulas 110 mg**  
**Pradaxa Cápsulas 150 mg**

**Claudia Mejías González**  
Teléfono: +56/2/327 50 45  
Telefax: +56/2/264 00 10  
Internet mail:  
claudia.mejias@boehringer-  
ingelheim.com

Estimados:

Por medio de la presente informamos a Ud, que los productos **Pradaxa Cápsulas 110 mg y Pradaxa Cápsulas 150 mg** registrados en Chile bajo los N° F-17448/14 y F-18648/16 respectivamente, fue aprobado por la FDA el 01 de agosto 2014, autorización número (NDA) 022512. Se adjunta documento obtenido de la base de datos de la FDA.

General del Canto # 421  
Piso 6 / Providencia  
Santiago/Chile  
Teléfono: +56/2/264 00 00  
Telefax: +56/2/264 00 10

Sin otro en particular, le saluda atte,  
BOEHRINGER INGELHEIM LTDA.



**Q.F. Claudia Mejías G.**  
**Directora Técnica**

 U.S. Department of Health & Human Services

 **U.S. FOOD & DRUG**  
ADMINISTRATION

A to Z Index | Follow FDA | En Español

SEARCH

Home | Food | Drugs | Medical Devices | Radiation-Emitting Products | Vaccines, Blood & Biologics | Animal & Veterinary | Cosmetics | Tobacco Products

FDA Home | Drug Databases | Drugs@FDA

  

FAQ | Instructions | Glossary | Contact Us

 Email Link

Start Over

Drug Details

|                                              |                               |
|----------------------------------------------|-------------------------------|
| Drug Name(s)                                 | PRADAXA                       |
| FDA Application No.                          | (NDA) 022512                  |
| Active Ingredient(s)                         | DABIGATRAN ETEXILATE MESYLATE |
| Company                                      | BOEHRINGER INGELHEIM          |
| Original Approval or Tentative Approval Date | October 19, 2010              |
| Chemical Type                                | 1 New molecular entity (NME)  |
| Review Classification                        | P Priority review drug        |

- There are no Therapeutic Equivalents
- Approval History, Letters, Reviews, and Related Documents
- Medication Guide

- Label Information
- Other Important Information from FDA

Products on Application (NDA) #022512

Click on a column header to re-sort the table:

| Drug Name | Active Ingredients            | Strength      | Dosage Form/Route | Marketing Status | RLD | TE Code |
|-----------|-------------------------------|---------------|-------------------|------------------|-----|---------|
| PRADAXA   | DABIGATRAN ETEXILATE MESYLATE | EQ 75MG BASE  | CAPSULE;ORAL      | Prescription     | No  | None    |
| PRADAXA   | DABIGATRAN ETEXILATE MESYLATE | EQ 150MG BASE | CAPSULE;ORAL      | Prescription     | Yes | None    |
| PRADAXA   | DABIGATRAN ETEXILATE MESYLATE | EQ 110MG BASE | CAPSULE;ORAL      | Prescription     | No  | None    |

Back to Top | Back to Previous Page | Back to Drugs@FDA Home

Disclaimer

FDA/Center for Drug Evaluation and Research  
Office of Communications  
Division of Online Communications  
Update Frequency: Daily

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).



Accessibility | Contact FDA | Careers | FDA Basics | FOIA | No FEAR Act | Site Map | Transparency | Website Policies

U.S. Food and Drug Administration  
10903 New Hampshire Avenue

Combination Products  
Advisory Committees

 U.S. Department of Health & Human Services

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails[06-10-2016 16:48:32]

Silver Spring, MD 20993  
Ph. 1-888-INFO-FDA (1-888-463-6332)  
[Contact FDA](#)



For Government

For Press

Science & Research

Regulatory Information

Safety

Emergency Preparedness

International Programs

News & Events

Training and Continuing Education

Inspections/Compliance

State & Local Officials

Consumers

Industry

Health Professionals

FDA Archive